Table 1.
Clinical and sociodemographic features of training and testing cohorts.
| Training and testing cohort | ||||
|---|---|---|---|---|
| N = 375 Model Set 1 (Metabolomic) | N = 348 Model Set 2 (Multi-omics) | |||
| Training Set N = 298 |
Testing Set N = 77 |
Training Set N = 277 |
Testing Set N = 71 |
|
| PGRN-AMPS patients (N) | 264 | 0 | 245 | 0 |
| CO-MED patients (N) | 34 | 77 | 32 | 71 |
| Sex [% female] | 66.1% | 71.4% | 65.3% | 70.4% |
| Age [mean (SD)] | 40.6 (13.3)* | 43.3 (11.5)* | 41.0 (13.3) | 43.4 (11.6) |
| Years of education [mean (SD)] | 14.7 (2.5)* | 13.9 (2.4)* | 14.8 (2.5)* | 13.9 (2.4)* |
| Race [% White] | 93.6%* | 77.9%* | 96.0%* | 77.5%* |
| Race [% Black or African American] | 3.4%* | 16.9%* | 2.2%* | 16.9%* |
| Race [% Other] | 3.0% | 5.2% | 1.8% | 5.6% |
| Ethnicity [% Hispanic] | 2.0%†* | 20.8%* | 1.4%†* | 21.1%* |
| Depression onset < age 18 years [%] | 43.6% | 39.0% | 41.5% | 39.4% |
| Prior suicide attempts [N (%)] | 46 (15.4%) | 7 (9.1%) | 40 (16.3%) | 6 (8.4%) |
| Antidepressants (N) |
Citalopram (112) Escitalopram (152) Escitalopram + Placebo (34) |
Venlafaxine + Mirtazapine (42) Escitalopram + Bupropion (35) |
Citalopram (99) Escitalopram (146) Escitalopram + Placebo (32) |
Venlafaxine + Mirtazapine (38) Escitalopram + Bupropion (33) |
| QIDS-C at baseline [mean (SD)] | 15.1 (3.4) | 15.5 (3.8) | 15.1 (3.3) | 15.3 (3.7) |
| QIDS-C response at week 4 | 47.0% | 40.2% | 47.7% | 42.2% |
| QIDS-C remission at week 4 | 26.2% | 26.0% | 26.7% | 28.2% |
| QIDS-C response at week 8 | 67.8% | 62.3% | 69.0% | 63.3% |
| QIDS-C remission at week 8 | 47.0% | 42.9% | 48.4% | 43.7% |
*Significantly different (p < 0.05) between training and testing sets according to Mann-Whitney U or chi-square tests. †Ethnicity characterization in PGRN-AMPS is based off data from 205 out of 264 patients, per availability of data.